

November 28, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 **National Stock Exchange of India Limited** 

Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip code: 512529 Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Ref: Composite scheme of amalgamation amongst Sequent Scientific Limited (Sequent), Symed Labs Limited (Symed), Vandana Life Sciences Private Limited (Vandana), Appcure Labs Private Limited (Appcure), Vindhya Pharma (India) Private Limited (Vindhya), S.V. Labs Private Limited (SV Labs), Vindhya Organics Private Limited (VOPL), Viyash Life Sciences Private Limited (Viyash), Geninn Life Sciences Private Limited (Geninn) and Sequent Research Limited (SRL) and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Scheme").

With reference to above, please note that as per the Scheme:

- a) approvals or events specified in Clauses 74.1.1 to 74.1.6 of the Scheme are satisfied; and
- b) certified copies of the order passed by the Hon'ble National Company Law Tribunal, Hyderabad bench dated November 18, 2025, sanctioning the Scheme, have been filed by Symed, Vandana, Appcure, Vindhya Pharma, SV Labs, VOPL, Geninn, and Viyash (as the transferee entity).

Accordingly, Parts II, III, IV, and V of the Scheme shall become effective from November 27, 2025, which shall be considered as 'Effective Date 1' for the Scheme.

Kindly take the same on record.

Thanking you,

Yours faithfully, For **Sequent Scientific Limited** 

Yoshita Vora
Company Secretary & Compliance Officer